引用本文： 陳萍,張慶,周俊,唐偉林,李莎莎,胡義德. 西妥昔單抗聯(lián)合放射和化學(xué)療法治療晚期鼻咽癌患者的觀察與護(hù)理. 華西醫(yī)學(xué), 2011, 26(5): 798-. doi: 復(fù)制
| 1. | Tham I, Lu J. Controversies and challenges in the current management of nasopharyngeal cancer[J]. Expert Rev Anticancer Ther, 2010, 10(9): 1439-1450. |
| 2. | Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck[J]. Curr Opin Oncol, 2008, 20(3): 256-263. |
| 3. | 呂汪霞,馬勝林. 西妥昔單抗的臨床研究新進(jìn)展[J]. 醫(yī)學(xué)綜述, 2010, 16(9): 1345-1348. |
| 4. | Pryor D, Porceddu S, Burmeister B, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer[J]. Radiother Oncol, 90(2): 172-176. |
| 5. | Baselga J. The EGFR as a targe for anti-cancer therapy focus on cetuximab[J]. Eur J Cancer, 2001, 37(Suppl 4): 16-22. |
| 6. | David E. Cetuximab in metastatic colorectal cancer[J]. London Cancer New Drugs Grorp-APC/DTC Briefing, 2005, 7(1): 1-10. |
- 1. Tham I, Lu J. Controversies and challenges in the current management of nasopharyngeal cancer[J]. Expert Rev Anticancer Ther, 2010, 10(9): 1439-1450.
- 2. Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck[J]. Curr Opin Oncol, 2008, 20(3): 256-263.
- 3. 呂汪霞,馬勝林. 西妥昔單抗的臨床研究新進(jìn)展[J]. 醫(yī)學(xué)綜述, 2010, 16(9): 1345-1348.
- 4. Pryor D, Porceddu S, Burmeister B, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer[J]. Radiother Oncol, 90(2): 172-176.
- 5. Baselga J. The EGFR as a targe for anti-cancer therapy focus on cetuximab[J]. Eur J Cancer, 2001, 37(Suppl 4): 16-22.
- 6. David E. Cetuximab in metastatic colorectal cancer[J]. London Cancer New Drugs Grorp-APC/DTC Briefing, 2005, 7(1): 1-10.